Efficacy of saccharomyces boulardii on necrotizing enterocolitis or sepsis in very low birth weight infants: A randomised controlled trial
Early Human Development, cilt.89, sa.12, ss.1033-1036, 2013 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 89 Sayı: 12
- Basım Tarihi: 2013
- Doi Numarası: 10.1016/j.earlhumdev.2013.08.013
- Dergi Adı: Early Human Development
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.1033-1036
- Anahtar Kelimeler: Necrotizing enterocolitis, Probiotics, Saccharomyces boulardii, Sepsis, Very low birth weight
- Sağlık Bilimleri Üniversitesi Adresli: Hayır
Özet
Background: Probiotics have strain specific effects and the effects of fungi in preventing diseases in preterm infants have been investigated poorly. Saccharomyces boulardii is a yeast which acts both as a probiotic and a polyamine producer. Aim: The objective of this study was to investigate the efficacy of S. boulardii in preventing necrotizing enterocolitis (NEC) or sepsis in very low birth weight infants. Study design and subjects: A prospective, double blind, placebo controlled trial was conducted in preterm infants (≤. 32 GWs, ≤. 1500. g birth weight). They were randomized either to receive feeding supplementation with S. boulardii 50. mg/kg every 12. h or placebo, starting with the first feed until discharged. Outcome measures: Necrotizing enterocolitis (NEC) or sepsis and NEC or death. Results: Birth weight and gestational age of the study (n= 104) and the control (n= 104) groups were 1126. ±. 232 vs 1162. ±. 216. g and 28.8. ±. 2.2 vs 28.7. ±. 2.1. weeks, respectively. Neither the incidence of stage ≥. 2 NEC or death nor stage ≥. 2 NEC or late onset culture proven sepsis was significantly lower in the study group when compared with the control group (9.6% vs 7.7%, p. = 0.62; 28.8% vs 23%, p= 0.34). Time to reach 100. mL/kg/day of enteral feeding (11.9. ±. 7 vs 12.6. ±. 7. days, p. = 0.37) was not different between the groups. Conclusions: Saccharomyces boulardii did not decrease the incidence of NEC or sepsis. © 2013 Elsevier Ltd.